- Email: [email protected]
Correction to Lancet Diabetes Endocrinol 2017; 5: 887–97
Corrections
Correction to Lancet Diabetes Endocrinol 2017; 5: 597–609 Petrie JR, Chaturvedi N, Ford I, et al, for the REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 597–609—In this Article, the spelling of the name of the collaborator Sam Philip, listed in the appendix, has been updated. This correction has been made to the online version as of Oct 24, 2017.
Correction to Lancet Diabetes Endocrinol 2017; 5: 877–86 Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo controlled trial. Lancet Diabetes Endocrinol 2017; 5: 877–86—In the Methods section
of this Article (published online on Sept 13, 2017), the information on study sites should read “outpatient clinics in tier 3 and tier 2 hospitals in China”. A new appendix has also been provided to include the acknowledgment of Jialun Chen. These corrections have been made to the online version as of Oct 24, 2017, and the printed Article is correct.
Correction to Lancet Diabetes Endocrinol 2017; 5: 887–97 Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5: 887–97—In this Article, the list of collaborators in the appendix has been updated. This correction has been made to the online version as of Oct 24, 2017, and the printed Article is correct.
www.thelancet.com/diabetes-endocrinology Vol 5 November 2017
Correction to Lancet Diabetes Endocrinol 2016; 4: 756–65 Lain SL, Bentley JP, Wiley V, et al. Association between borderline neonatal thyroid-stimulating hormone concentrations and educational and developmental outcomes: a population-based record-linkage study. Lancet Diabetes Endocrinol 2016; 4: 756–65—In this Article, congenital hypothyroidism was incorrectly changed to congenital hyperthyroidism in the editing of the Discussion section. This correction has been made to the online version as of Sept 22, 2017.
Published Online September 22, 2017 http://dx.doi.org/10.1016/ S2213-8587(17)30330-3
e7
Correction to Lancet Diabetes Endocrinol 2017; 5: 597–609 Petrie JR, Chaturvedi N, Ford I, et al, for the REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 597–609—In this Article, the spelling of the name of the collaborator Sam Philip, listed in the appendix, has been updated. This correction has been made to the online version as of Oct 24, 2017.
Correction to Lancet Diabetes Endocrinol 2017; 5: 877–86 Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo controlled trial. Lancet Diabetes Endocrinol 2017; 5: 877–86—In the Methods section
of this Article (published online on Sept 13, 2017), the information on study sites should read “outpatient clinics in tier 3 and tier 2 hospitals in China”. A new appendix has also been provided to include the acknowledgment of Jialun Chen. These corrections have been made to the online version as of Oct 24, 2017, and the printed Article is correct.
Correction to Lancet Diabetes Endocrinol 2017; 5: 887–97 Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5: 887–97—In this Article, the list of collaborators in the appendix has been updated. This correction has been made to the online version as of Oct 24, 2017, and the printed Article is correct.
www.thelancet.com/diabetes-endocrinology Vol 5 November 2017
Correction to Lancet Diabetes Endocrinol 2016; 4: 756–65 Lain SL, Bentley JP, Wiley V, et al. Association between borderline neonatal thyroid-stimulating hormone concentrations and educational and developmental outcomes: a population-based record-linkage study. Lancet Diabetes Endocrinol 2016; 4: 756–65—In this Article, congenital hypothyroidism was incorrectly changed to congenital hyperthyroidism in the editing of the Discussion section. This correction has been made to the online version as of Sept 22, 2017.
Published Online September 22, 2017 http://dx.doi.org/10.1016/ S2213-8587(17)30330-3
e7